View Clinical Trial (Medical Research Study)
Dopamine and Insulin Resistance
| City: |
|
Nashville |
| State: |
|
Tennessee |
| Zip Code: |
|
37232 |
| Conditions: |
|
Obesity |
| Purpose: |
|
Obese individuals have fewer striatal dopamine type 2 receptors (DRD2) than normal weight
individuals. Lower DRD2 levels are associated with addiction and a decreased sense of
pleasure.Obesity is also associated with insulin resistance (poor insulin action).We propose
that insulin resistance and low DRD2 are associated. Using PET imaging,we aim to determine
DRD2 binding potential (BP) in the brain is associated with insulin resistance and
neuroendocrine hormone levels. Obese participants will be compared to lean, gender and age
similar participants. We also aim to determine the effect of caloric restriction on DRD2 BP
in obese subjects
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Ages 18-60 yrs
- obese BMI > 30kg/m2 and Weight less than 350 lbs
- lean control BMI 18-25kg/m2
Exclusion Criteria:
- Structured exercise > equivalent to 30mins 5x week of walking times a week
- History of Substance Abuse, including but exclusive to alcohol, cocaine, marijuana,
heroin, nicotine
- Current psychiatric disorder or significant h/o disorder
- Use or any antidepressants or antipsychotics for last 3-6months or depot
antipsychotics in the last 12 months
- Any condition felt by PI or co-investigators to interfere with ability to complete
the study
- Inability to abstain from alcohol, physical exercise or > 1 cup of coffee or
equivalent daily for 3 days prior to imaging studies
- Significant co-morbidities including atherosclerotic disease, metabolic disease,
liver or renal insufficiency or abnormality found on MRI
- Any condition which would interfere with MRI or PET studies, e.g. claustrophobia,
cochlear implant, metal fragments in eyes, cardiac pacemaker, neural stimulator,
tattoos with iron pigment and metallic body inclusions or other metal implanted in
the body which may interfere with MRI scanning
- Subjects on medications determined by PI, ex. sibutramine, frequent benzodiazepines
or related drugs, which could affect quality of study for last 3 months.
|
| NCT ID: |
|
NCT00802204 |
| Primary Contact: |
|
Principal Investigator
Julia P Dunn, MD
Vanderbilt University
Pamela A Marks, MS, RD
Phone: 615-343-8389
Email: pamela.a.marks@vanderbilt.edu
|
| Backup Contact: |
|
Email: obesityresearch@vanderbilt.edu
Julia P Dunn, MD
Phone: 615-322-3957
|
| Location Contact: |
|
Nashville, Tennessee 37232
United States
Marks
Email: obesityresearch@vanderbilt.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|